Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G A Rodan

Showing results (191-200 of 200) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 200 results.
Cancer Research|September 15, 1987
Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic propertiesS B Rodan, Y Imai, M A Thiede, et al.
Endocrinology|March 1, 1993
Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing proteinJ E Fisher, M P Caulfield, M Sato, et al.
Bone|December 20, 2005
Preservation of thoracic spine microarchitecture by alendronate: comparison of histology and microCTL D Hordon, M Itoda, P A Shore, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 27, 1998
High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cellsD D Diascro, R L Vogel, T E Johnson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 1, 1993
Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized ratsD B Lauritzen, R Balena, M Shea, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 2, 1996
Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronateA Schmidt, S J Rutledge, N Endo, et al.
The Journal of Clinical Investigation|October 1, 1983
Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cellsS B Rodan, K L Insogna, A M Vignery, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 6, 1999
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitroJ E Fisher, M J Rogers, J M Halasy, et al.
Molecular Pharmacology|June 16, 2001
Prostaglandin receptor EP(4) mediates the bone anabolic effects of PGE(2)M Machwate, S Harada, C T Leu, et al.
Journal of Medicinal Chemistry|October 6, 2000
Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonistM E Duggan, L T Duong, J E Fisher, et al.
Pageof 20

Showing results (191-200 of 200) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 200 results.
Cancer Research|September 15, 1987
Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic propertiesS B Rodan, Y Imai, M A Thiede, et al.
Endocrinology|March 1, 1993
Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing proteinJ E Fisher, M P Caulfield, M Sato, et al.
Bone|December 20, 2005
Preservation of thoracic spine microarchitecture by alendronate: comparison of histology and microCTL D Hordon, M Itoda, P A Shore, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 27, 1998
High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cellsD D Diascro, R L Vogel, T E Johnson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 1, 1993
Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized ratsD B Lauritzen, R Balena, M Shea, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 2, 1996
Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronateA Schmidt, S J Rutledge, N Endo, et al.
The Journal of Clinical Investigation|October 1, 1983
Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cellsS B Rodan, K L Insogna, A M Vignery, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 6, 1999
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitroJ E Fisher, M J Rogers, J M Halasy, et al.
Molecular Pharmacology|June 16, 2001
Prostaglandin receptor EP(4) mediates the bone anabolic effects of PGE(2)M Machwate, S Harada, C T Leu, et al.
Journal of Medicinal Chemistry|October 6, 2000
Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonistM E Duggan, L T Duong, J E Fisher, et al.
Pageof 20